Bristol-Myers Squibb (BMY)
56.60
0.00 (0.00%)
Upcoming Events
Latest Headlines
Arcus Biosciences partners with Bristol Myers Squibb on kidney cancer trial
June 3, 2026 8:01 AM - StreetInsider
Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
June 3, 2026 8:00 AM - BizWire
Bristol Myers Squibb drug shows survival benefit in cancer trials
June 2, 2026 8:02 AM - StreetInsider
Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Patients with Triple-Negative Brea
June 2, 2026 8:00 AM - BizWire
FDA accepts Bristol Myers Squibb Camzyos application for adolescent treatment
June 1, 2026 6:59 AM - StreetInsider
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Supplemental New Drug Application for Camzyos (mavacamten) to Treat Adolescents with Symptomatic Obstructive Hype
June 1, 2026 6:59 AM - BizWire
Bristol Myers Squibb gains EU approval for Opdivo combination in lymphoma
June 1, 2026 6:56 AM - StreetInsider
Bristol Myers Squibb Announces Opdivo® (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Lymphoma
June 1, 2026 6:55 AM - BizWire
Bristol Myers Squibb drug reduces multiple myeloma progression risk by 52%
May 29, 2026 8:02 AM - StreetInsider
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
May 29, 2026 8:00 AM - BizWire
UBS Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
May 28, 2026 10:09 AM - StreetInsider
Bristol Myers Squibb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
May 27, 2026 6:59 AM - BizWire
Bristol Myers Squibb to present 60+ oncology studies at ASCO 2026
May 21, 2026 5:01 PM - StreetInsider
Bristol Myers Squibb to Unveil New Data at ASCO® 2026 Demonstrating Strength and Breadth of Scientific Innovation Across Oncology Portfolio and Next-Generation Pipeline
May 21, 2026 5:01 PM - BizWire
Bristol Myers to deploy Anthropic's Claude AI model to speed up drug discovery
May 20, 2026 7:48 AM - StreetInsider
Bristol Myers Squibb partners with Anthropic to deploy AI across operations
May 20, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Announces Strategic Agreement with Anthropic to Position Claude Enterprise as the Shared Intelligence Platform Across Its Global Operations
May 20, 2026 6:59 AM - BizWire
Bristol-Myers Squibb (BMY) brings Anthropic’s Claude to 30,000 of its staff - WSJ
May 20, 2026 6:54 AM - StreetInsider
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience
May 14, 2026 8:30 AM - BizWire
Bernstein SocGen on Bristol-Myers Squibb Co. (BMY): 'Hengrui deal highlights acceleration possibilities in China'
May 13, 2026 8:04 AM - StreetInsider
Pacira BioSciences urges stockholders to support board nominees
May 12, 2026 4:01 PM - StreetInsider
Pacira BioSciences Sends Letter to Stockholders Reiterating Superior Qualifications of its Board Nominees
May 12, 2026 4:01 PM - StreetInsider
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
May 12, 2026 10:34 AM - StreetInsider
Form S-8 BRISTOL MYERS SQUIBB CO
May 8, 2026 4:34 PM - SEC Filing
Form 8-K BRISTOL MYERS SQUIBB CO For: May 05
May 8, 2026 4:12 PM - SEC Filing
Bristol Myers Squibb gets EU approval for Sotyktu to treat psoriatic arthritis
May 8, 2026 7:00 AM - StreetInsider
Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib) for the Treatment of Active Psoriatic Arthritis in Adults
May 8, 2026 6:59 AM - BizWire
Bristol Myers Squibb to Participate in the Bank of America Securities Healthcare Conference 2026
May 6, 2026 6:59 AM - BizWire
Form 4 BRISTOL MYERS SQUIBB CO For: May 01 Filed by: Lenkowsky Adam
May 5, 2026 5:11 PM - SEC Filing
BMO Capital Reiterates Market Perform Rating on Bristol-Myers Squibb Co. (BMY)
May 4, 2026 7:29 AM - StreetInsider
Bristol Myers Squibb Launches “Won't Lose” Media Campaign Ahead of FIFA World Cup 2026™
May 4, 2026 6:59 AM - BizWire
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at BMO Capital
May 1, 2026 4:10 AM - StreetInsider
BofA: Bristol update may boost Cytokinetics shares
April 30, 2026 12:12 PM - StreetInsider
Form 10-Q BRISTOL MYERS SQUIBB CO For: Mar 31
April 30, 2026 11:45 AM - SEC Filing
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook
April 30, 2026 7:21 AM - StreetInsider
Bristol-Myers Squibb (BMY) Tops Q1 EPS by 16c; reaffirms guidance
April 30, 2026 7:03 AM - StreetInsider
Form 8-K BRISTOL MYERS SQUIBB CO For: Apr 30
April 30, 2026 7:02 AM - SEC Filing
Bristol Myers Squibb Reports First Quarter Financial Results for 2026
April 30, 2026 6:59 AM - BizWire
Form SCHEDULE 13G BRISTOL MYERS SQUIBB CO Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 5:09 PM - SEC Filing
Bristol Myers Squibb and Pfizer partner with Mark Cuban's Cost Plus Drugs
April 24, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb and Pfizer to Make Eliquis® (apixaban) Available via Mark Cuban Cost Plus Drug Company
April 24, 2026 6:59 AM - BizWire
Atrium Therapeutics receives $15 million milestone from Bristol Myers Squibb
April 23, 2026 8:01 AM - StreetInsider
Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
April 23, 2026 8:00 AM - PR NewsWire
Foundation Medicine Expands Existing Collaboration with Bristol Myers Squibb to Develop a Next-Generation Sequencing Companion Diagnostic to Identify Patients with Homozygous MTAP Deletion
April 21, 2026 7:00 AM - BizWire
Ardelyx names Felecia Ettenberg as chief legal officer
April 20, 2026 8:00 AM - StreetInsider
Ardelyx Appoints Biopharmaceutical Veteran, Felecia W. Ettenberg, as Chief Legal Officer
April 20, 2026 8:00 AM - Globe NewsWire
Form DEFA14A BRISTOL MYERS SQUIBB CO
April 17, 2026 4:16 PM - SEC Filing
Raymond James Preview Bristol-Myers Squibb Co. (BMY) Earnings: 'Our updated diluted non-GAAP EPS is $1.49 for 1Q26 '
April 15, 2026 10:36 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Lowered to $67 at BofA Securities
April 9, 2026 9:30 AM - StreetInsider
Bristol-Myers Squibb (BMY) Reiterated at Neutral by Cantor Fitzgerald on Eliquis Outlook
April 8, 2026 7:33 AM - StreetInsider
Guggenheim Reiterates Buy Rating on Bristol-Myers Squibb Co. (BMY)
April 8, 2026 6:55 AM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Apr 01 Filed by: Shanahan Karin
April 2, 2026 4:31 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Apr 01 Filed by: Elkins David V
April 2, 2026 4:29 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 31 Filed by: YALE PHYLLIS R
April 2, 2026 4:28 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 31 Filed by: Samuels Theodore R. II
April 2, 2026 4:27 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 31 Filed by: Rice Derica W
April 2, 2026 4:26 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 31 Filed by: McMullen Michael R.
April 2, 2026 4:25 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 31 Filed by: Arduini Peter J
April 2, 2026 4:24 PM - SEC Filing
Form 144 BRISTOL MYERS SQUIBB CO Filed by: Elkins David V
April 1, 2026 4:34 PM - SEC Filing
Bristol Myers Squibb Evolves and Expands Standing in the Gaap To Advance More Equitable Care in Multiple Myeloma As Program Marks Ten Years
April 1, 2026 7:29 AM - StreetInsider
Bristol Myers Squibb expands multiple myeloma care program after decade
March 31, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
March 31, 2026 6:59 AM - BizWire
Bristol Myers Squibb study shows stable symptom transition to COBENFY
March 30, 2026 4:21 AM - StreetInsider
Bristol Myers Squibb drug shows promise in adolescent heart trial
March 29, 2026 11:45 AM - StreetInsider
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyo
March 29, 2026 11:45 AM - BizWire
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
March 28, 2026 7:00 AM - BizWire
Form 15-12G BRISTOL MYERS SQUIBB CO
March 27, 2026 4:05 PM - SEC Filing
A New Era in Schizophrenia Care: National Council for Mental Wellbeing and Bristol Myers Squibb Collaborate to Advance Evidence-Based Care Models
March 27, 2026 7:29 AM - StreetInsider
Form SCHEDULE 13G/A BRISTOL MYERS SQUIBB CO Filed by: VANGUARD GROUP INC
March 26, 2026 4:45 PM - SEC Filing
Form ARS BRISTOL MYERS SQUIBB CO For: Dec 31
March 25, 2026 5:18 PM - SEC Filing
Form DEFA14A BRISTOL MYERS SQUIBB CO
March 25, 2026 4:36 PM - SEC Filing
Form DEF 14A BRISTOL MYERS SQUIBB CO For: May 05
March 25, 2026 4:19 PM - SEC Filing
Three New Studies Show Viz.ai’s Cardio Suite Speeds Detection of Cardiac Disease and Improves Patient Follow-Up
March 23, 2026 9:00 AM - BizWire
insitro expands Bristol Myers Squibb partnership with two new ALS targets
March 23, 2026 8:00 AM - StreetInsider
insitro and Bristol Myers Squibb Collaboration Expanded with Nomination of New Targets
March 23, 2026 8:00 AM - BizWire
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
March 23, 2026 6:59 AM - BizWire
Bristol Myers Squibb wins FDA and EU approvals for Opdivo in Hodgkin lymphoma
March 20, 2026 4:42 PM - StreetInsider
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
March 20, 2026 4:42 PM - BizWire
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
March 19, 2026 6:59 AM - BizWire
RBC Capital on Biopharma: 'M&A Discussion, Whether Accurate Or Not, Can Drive Returns'
March 18, 2026 9:21 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $70 at Jefferies: SUCCESSOR-2 interim validates CELMoD strategy
March 17, 2026 8:26 AM - StreetInsider
Bristol-Myers Squibb Co. (BMY) PT Raised to $60 at HSBC
March 17, 2026 3:39 AM - StreetInsider
Raymond James looks for further durability in BMY's (BMY) MountainTAP-30 trial
March 16, 2026 4:28 PM - StreetInsider
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hickey Benjamin
March 12, 2026 4:26 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shibutani Hiroshi Chris
March 12, 2026 4:26 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Massacesi Cristian
March 12, 2026 4:25 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Short Bartie Wendy
March 12, 2026 4:23 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Shanahan Karin
March 12, 2026 4:23 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Plenge Robert M
March 12, 2026 4:22 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Meyers Gregory Scott
March 12, 2026 4:20 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Lenkowsky Adam
March 12, 2026 4:20 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Holzer Phil M
March 12, 2026 4:20 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Hoch Lynelle
March 12, 2026 4:18 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Gallman Cari
March 12, 2026 4:18 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Poole Ahn Amanda
March 12, 2026 4:18 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: BOERNER CHRISTOPHER S.
March 12, 2026 4:15 PM - SEC Filing
Form 4 BRISTOL MYERS SQUIBB CO For: Mar 10 Filed by: Elkins David V
March 12, 2026 4:15 PM - SEC Filing
Bristol Myers Squibb reports positive phase 3 results for myeloma drug
March 9, 2026 6:59 AM - StreetInsider
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
March 9, 2026 6:59 AM - BizWire
Full Article List
